Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066343 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL13157330 | 0.91 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL1767370 | 0.91 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL13948109 | 0.91 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL1767369 | 0.91 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL13853902 | 0.86 | NOD1 (0.54) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL14538464 | 0.86 | PTGS1 (0.55) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL677435 | 0.85 | PTGS1 (0.80) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL13160954 | 0.85 | PTGS1 (0.80) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL18813885 | 0.85 | PTGS1 (0.41) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | PTGS1 1042/4885GSTK1 917/4885GLO1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.